These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 25916521)
1. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Stimpfle F; Geisler T Pharmacogenomics; 2015; 16(5):493-9. PubMed ID: 25916521 [TBL] [Abstract][Full Text] [Related]
2. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Straub N; Beivers A; Lenk E; Aradi D; Sibbing D Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566 [TBL] [Abstract][Full Text] [Related]
3. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303 [TBL] [Abstract][Full Text] [Related]
13. Platelet function testing in patients with acute coronary syndrome. Orban M; Sibbing D J Cardiovasc Transl Res; 2013 Jun; 6(3):371-7. PubMed ID: 23397280 [TBL] [Abstract][Full Text] [Related]
14. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Sibbing D; Orban M; Massberg S Hamostaseologie; 2013; 33(1):9-15. PubMed ID: 23299202 [TBL] [Abstract][Full Text] [Related]
15. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Bernlochner I; Byrne RA; Kastrati A; Sibbing D Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045 [TBL] [Abstract][Full Text] [Related]
16. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528 [TBL] [Abstract][Full Text] [Related]
17. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K; Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675 [TBL] [Abstract][Full Text] [Related]
18. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Coleman CI; Limone BL Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863 [TBL] [Abstract][Full Text] [Related]